Neal Cutler, MD
Founder & Chief Executive Officer
Neal R. Cutler, MD, Founder & Chief Executive Officer at Worldwide Clinical Trials, has more than 30 years of experience in the clinical research space. He has been instrumental in the development and investigation of almost 300 compounds and has advanced revolutionary study methodologies. His medical credentials include board certifications in psychiatry, neurology, and clinical pharmacology. His innovative spirit is based on medicine and science, and his pioneering energy at both the organizational and operational level has distinguished him as a true visionary within the industry.
ABOUT NEAL CUTLER, MD
Dr. Neal Cutler is the CEO and founder of Worldwide Clinical Trials, a global CRO that offers a full range of product development services to the pharmaceutical and biotechnology industries. He has held this position since 2007. From 2000–2006, Dr. Cutler founded and served as president and CEO of Alamo Pharmaceuticals LLC. During this time, Dr. Cutler also developed and obtained FDA approval for a new drug to treat schizophrenia, FazaClo®, which is on the market today. He successfully merged Alamo into Avanir Pharmaceuticals in 2006.
Dr. Cutler was founder and director of California Clinical Trials from 1987–1999, which was one of the largest Phase I–III clinical pharmacology and investigational sites in the United States. The company was expanded into a global CRO, also named Worldwide Clinical Trials, which he successfully merged into a subsidiary of UnitedHealth Group Inc.
Dr. Cutler is a board-certified psychiatrist and board qualified in both neurology and clinical pharmacology. He worked at the National Institutes of Health (NIH) for over nine years, serving as both the section chief for the Laboratory of Neuroscience and as deputy clinical director of the National Institute on Aging (NIA). He also served as expert to the Food and Drug Administration Division of Neuropharmacological Agents from 1981–-1983. He was previously president of the American Foundation for Clinical Pharmacology and served on a special emphasis panel review committee for the National Institute on Aging for the NIH.
Dr. Cutler has been instrumental in the design and clinical development of over 300 compounds in numerous therapeutic areas, with particular expertise in central nervous system disorders. He developed the revolutionary “dynabridge” and “bridging” study methodologies, which made feasible the study of the dynamic activity of a compound in the brain and facilitated the rapid and effective development of a number of subsequent compounds.
Dr. Cutler has given several hundred international and national presentations in the fields of aging, migraine, clinical pharmacology, and drug development. He has authored over 280 publications, including 9 books on the topics of clinical pharmacology, aging, Alzheimer’s disease, schizophrenia disorders, anxiety, and diabetes.